Massachusetts Financial Services Co. MA Has $29.96 Million Stake in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Massachusetts Financial Services Co. MA cut its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 5.2% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 307,006 shares of the medical equipment provider's stock after selling 16,894 shares during the period. Massachusetts Financial Services Co. MA owned approximately 0.45% of Lantheus worth $29,964,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the business. Janus Henderson Group PLC lifted its position in shares of Lantheus by 72.7% in the 4th quarter. Janus Henderson Group PLC now owns 6,198,689 shares of the medical equipment provider's stock valued at $554,583,000 after acquiring an additional 2,610,118 shares in the last quarter. Farallon Capital Management LLC grew its stake in Lantheus by 79.9% in the 4th quarter. Farallon Capital Management LLC now owns 5,316,227 shares of the medical equipment provider's stock valued at $475,590,000 after buying an additional 2,361,000 shares during the last quarter. T. Rowe Price Investment Management Inc. grew its stake in Lantheus by 40.5% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,509,332 shares of the medical equipment provider's stock valued at $135,025,000 after buying an additional 435,445 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in Lantheus in the 4th quarter worth $36,183,000. Finally, Assenagon Asset Management S.A. grew its position in Lantheus by 1,196.4% in the 1st quarter. Assenagon Asset Management S.A. now owns 336,237 shares of the medical equipment provider's stock worth $32,817,000 after purchasing an additional 310,301 shares during the last quarter. 99.06% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Lantheus

In other news, Director Mary Anne Heino sold 26,066 shares of the firm's stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $76.83, for a total value of $2,002,650.78. Following the sale, the director directly owned 318,650 shares in the company, valued at approximately $24,481,879.50. This trade represents a 7.56% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 1.50% of the stock is owned by insiders.

Lantheus Stock Performance

Shares of LNTH traded down $3.42 during trading hours on Friday, hitting $70.18. The company had a trading volume of 1,351,740 shares, compared to its average volume of 982,124. Lantheus Holdings, Inc. has a 12 month low of $69.12 and a 12 month high of $118.21. The firm has a market cap of $4.86 billion, a price-to-earnings ratio of 19.94 and a beta of 0.12. The business has a fifty day moving average of $78.80 and a 200-day moving average of $89.44. The company has a quick ratio of 5.46, a current ratio of 5.74 and a debt-to-equity ratio of 0.49.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 EPS for the quarter, missing analysts' consensus estimates of $1.64 by ($0.11). Lantheus had a return on equity of 36.99% and a net margin of 16.55%. The business had revenue of $372.76 million for the quarter, compared to the consensus estimate of $377.37 million. During the same period in the prior year, the business posted $1.69 earnings per share. Lantheus's revenue was up .8% compared to the same quarter last year. Equities analysts anticipate that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the stock. B. Riley cut their price target on shares of Lantheus from $122.00 to $109.00 and set a "buy" rating for the company in a report on Monday, June 23rd. Truist Financial decreased their price objective on shares of Lantheus from $127.00 to $117.00 and set a "buy" rating for the company in a report on Thursday, May 8th. Wall Street Zen upgraded shares of Lantheus from a "hold" rating to a "buy" rating in a report on Thursday, May 8th. Finally, William Blair restated a "market perform" rating on shares of Lantheus in a report on Wednesday. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $131.20.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.